TY - JOUR
T1 - A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions
AU - Kaiser, P. K.
AU - Pineda, R.
AU - An, B.
AU - Brun, S.
AU - Burk, S.
AU - Kim, R.
AU - Krzystolik, M.
AU - Graham, K.
AU - Nguyen, Q.
AU - Rowe, S.
AU - Ryan-Graham, M.
AU - Smith, J.
AU - Vinals, A.
AU - Yoo, S.
AU - You, T.
N1 - Funding Information:
Originally received: October 31, 1995. Revision accepted: March II, 1997. I The Cleveland Clinic Foundation. Cleveland, Ohio. 2 The Massachusetts Eye and Ear Infirmary. Harvard Medical School, Boston. Massachusetts. Presented at the American Academy of Ophthalmology Annual Meeting, Atlanta, November 1995. Supported in part by an unrestricted grant from Allergan, Inc .• Irvine, California. The authors and their families have no commercial or proprietary interest in any of the materials. methods, or results described in this study. Address correspondence to Peter K. Kaiser. MD. Division of Ophthalmology A31, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.
PY - 1997
Y1 - 1997
N2 - Objective: To evaluate the effectiveness of an ophthalmic nonsteroidal anti-inflammatory drug (NSAID) in the treatment of noninfected, non-contact lens-related, traumatic corneal abrasions and no pressure patch. Design: A single-center, randomized, double-masked, placebo-controlled study. Participants: One hundred patients with noninfected, non-contact lens- related, traumatic or foreign body removal-related corneal abrasions less than 36 hours in duration. Intervention: All patients received a cycloplegic drop and erythromycin or polymyxin B (Polysporin Ophthalmic Ointment, Burroughs Wellcome, Research Triangle Park, NC). Patients were then randomized to receive either ketorolac tromethamine 0.5% ophthalmic solution or control vehicle drops. Main Outcome Measures: The main outcome measures were six subjective symptoms monitored daily, evaluation of corneal abrasion, and determination of adverse events. Long-term complications were determined 3 to 8 months after randomization. Results: Twelve patients were excluded from the study. One day after randomization, patients receiving ketorolac tromethamine 0.5% ophthalmic solution noted significantly decreased levels of pain (P < 0.002), photophobia (P < 0.009), and foreign body sensation (P < 0.003) as compared with the control vehicle group. In addition, the time to resumption of normal activities was shorter in the group who received ketorolac tromethamine 0.5% ophthalmic solution (P < 0.001). There was no statistical difference in the amount of tearing, healing time, acuity changes, or complication rates between the two groups. Conclusions: Ketorolac tromethamine 0.5% ophthalmic solution provides increased patient comfort without clinical adverse effects when used as adjunctive therapy in the treatment of noninfected, non-contact lens-related, traumatic corneal abrasions.
AB - Objective: To evaluate the effectiveness of an ophthalmic nonsteroidal anti-inflammatory drug (NSAID) in the treatment of noninfected, non-contact lens-related, traumatic corneal abrasions and no pressure patch. Design: A single-center, randomized, double-masked, placebo-controlled study. Participants: One hundred patients with noninfected, non-contact lens- related, traumatic or foreign body removal-related corneal abrasions less than 36 hours in duration. Intervention: All patients received a cycloplegic drop and erythromycin or polymyxin B (Polysporin Ophthalmic Ointment, Burroughs Wellcome, Research Triangle Park, NC). Patients were then randomized to receive either ketorolac tromethamine 0.5% ophthalmic solution or control vehicle drops. Main Outcome Measures: The main outcome measures were six subjective symptoms monitored daily, evaluation of corneal abrasion, and determination of adverse events. Long-term complications were determined 3 to 8 months after randomization. Results: Twelve patients were excluded from the study. One day after randomization, patients receiving ketorolac tromethamine 0.5% ophthalmic solution noted significantly decreased levels of pain (P < 0.002), photophobia (P < 0.009), and foreign body sensation (P < 0.003) as compared with the control vehicle group. In addition, the time to resumption of normal activities was shorter in the group who received ketorolac tromethamine 0.5% ophthalmic solution (P < 0.001). There was no statistical difference in the amount of tearing, healing time, acuity changes, or complication rates between the two groups. Conclusions: Ketorolac tromethamine 0.5% ophthalmic solution provides increased patient comfort without clinical adverse effects when used as adjunctive therapy in the treatment of noninfected, non-contact lens-related, traumatic corneal abrasions.
UR - http://www.scopus.com/inward/record.url?scp=6844252898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=6844252898&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(97)30135-3
DO - 10.1016/S0161-6420(97)30135-3
M3 - Article
C2 - 9261326
AN - SCOPUS:6844252898
SN - 0161-6420
VL - 104
SP - 1353
EP - 1359
JO - Ophthalmology
JF - Ophthalmology
IS - 8
ER -